<div class="headers"><div>Figure 3: Treatment di<U+FB00> erences between evolocumab and placebo in mean percentage changes from baseline in LDL cholesterol at week 12 and the associations with sex, age, BMI, lipid-lowering therapy, and baseline LDL cholesterol concentrations (A) Doses administered every 2 weeks. (B) Doses administered monthly. Error bars are 95% CI. BMI=body-mass index. NA=not available.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<thead>
<tr>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey;'> </th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>row/col</th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>8(H)</th>
</tr>
</thead>
<tbody>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">Figure 3: Treatment di<U+FB00> erences between evolocumab and placebo in mean percentage changes from baseline in LDL cholesterol at week 12 and the associations with sex, age, BMI, lipid-lowering therapy, and baseline LDL cholesterol concentrations (A) Doses administered every 2 weeks. (B) Doses administered monthly. Error bars are 95% CI. BMI=body-mass index. NA=not available.</p></td>
</tr>
</tbody>
</table>
